2003 Canadian clinical practice guidelines for the management of diabetes in children and adolescents

Paediatrics and Child Health

Volumn 10, Issue SUPPL. A, 2005, Pages

  Lawson, Margaret L ^a   Pacaud, Danièle ^b   Lawrence, Sarah E ^a   Daneman, Denis ^c   Dean, Heather J ^d  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Adolescents; Children; Diabetes; Diagnosis; Guidelines; Management

Indexed keywords

ALBUMIN; BICARBONATE; CHOLESTEROL; CORTICOTROPIN; ENDOMYSIUM ANTIBODY; GLUCOSE; HEMOGLOBIN A1C; HYDROCORTISONE; IMMUNOGLOBULIN A; INFLUENZA VACCINE; INSULIN; PNEUMOCOCCUS VACCINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; THYROTROPIN;

ADDISON DISEASE; ADOLESCENT; CANADA; CELIAC DISEASE; CHILD; CIGARETTE SMOKING; CLINICAL PRACTICE; COMORBIDITY; CONTRACEPTION; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE CLASSIFICATION; DYSLIPIDEMIA; EATING DISORDER; ETHNIC GROUP; FAMILY HISTORY; FLUID THERAPY; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IMMUNIZATION; IMPAIRED GLUCOSE TOLERANCE; INFLUENZA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; LABORATORY TEST; MAJOR CLINICAL STUDY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COUNSELING; PRACTICE GUIDELINE; REVIEW; SCREENING TEST; SEXUAL EDUCATION; SMOKING CESSATION; STREPTOCOCCUS INFECTION;

EID: 14944352302     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/10.suppl_a.5a     Document Type: Review

References (128)

1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(Suppl 2):S1-S152. 〈www.diabetes.ca/ cpg2003/default.aspx〉 (Version current at November 22, 2004).
2. Meltzer S, Leiter L, Daneman D, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ. 1998;159(Suppl 8):S1-29.
3. Curtis J, Hamilton J, Beck C, Frank M, Daneman D. Diagnosis and short-term clinical consequences of diabetes in children and adolescents. In: Gerstein HC, Haynes RB, eds. Evidenced-based Diabetes Care. Hamilton: BC Decker Inc, 2001:107-23.
4. Charron-Prochownik D, Maihle T, Siminerio L, Songer T. Outpatient versus inpatient care of children newly diagnosed with IDDM. Diabetes Care 1997;20:657-60.
5. Siminerio LM, Charron-Prochownik D, Banion C, Schreiner B. Comparing outpatient and inpatient diabetes education for newly diagnosed pediatric patients. Diabetes Educ 1999;25:895-906.
6. Chase HP, Crews KR, Garg S, et al. Outpatient management vs in-hospital management of children with new-onset diabetes. Clin Pediatr (Phila) 1992;31:450-6.
7. Daneman D, Frank M. Defining quality of care for children and adolescents with type 1 diabetes. Acta Paediatr Suppl 1998;425:11-9.
8. Dougherty G, Schiffrin A, White D, Soderstrom L, Sufrategui M. Home-based management can achieve intensification cost-effectively in type I diabetes. Pediatrics 1999;103:122-8.
9. Glasgow AM, Weissberg-Benchell J, Tynan WD, et al. Readmissions of children with diabetes mellitus to a children's hospital. Pediatrics 1991;88:98-104.
10. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994;125:177-88.
11. Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-83.
12. Hershey T, Craft S, Bhargava N, White NH. Memory and insulin dependent diabetes mellitus (IDDM): Effects of childhood onset and severe hypoglycemia. J Int Neuropsychol Soc 1997;3:509-20.
13. Rovet J, Alvarez M. Attentional functioning in children and adolescents with IDDM. Diabetes Care 1997;20:803-10.
14. Rovet JF, Ehrlich RM. The effect of hypoglycemic seizures on cognitive function in children with diabetes:A 7-year prospective study. J Pediatr 1999;134:503-6.
15. Bjorgaas M, Gimse R, Vik T, Sand T. Cognitive function in type 1 diabetic children with and without episodes of severe hypoglycaemia. Acta Paediart 1997;86:148-53.
16. Northam EA, Anderson PJ, Jacobs R, Hughes M, Warne GL, Werther GA. Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. Diabetes Care 2001;24:1541-6.
17. Yale JF, Begg I, Gerstein HC, et al. Canadian Diabetes Association clinical practice guidelines for the prevention and management of hypoglycemia in diabetes. Can J Diabetes 2001;26:22-35.
18. Ryan C, Vega A, Drash A. Cognitive deficits in adolescents who developed diabetes early in life. Pediatrics 1985:75:921-7.
19. Hershey T, Bhargava N, Sadler M, White NH, Craft S. Conventional versus intensive diabetes therapy in children with type 1 diabetes: Effects on memory and motor speed. Diabetes Care 1999;22:1318-24.
20. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes 1997;46:440-3.
21. Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP. Continuous subcutaneous insulin infusion therapy for children and adolescents: An option for routine diabetes care. Pediatrics 2001:107:351-6.
22. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999;22:1779-84.
23. Conrad S, McGrath M, Gitelman S. Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr 2002;140:235-40.
24. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15:369-76.
25. Mohn A, Strang S, Wernicke-Panten K, Lang AM, Edge JA, Dunger DB. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care 2000;23:557-9.
26. Chase HP, Garg SK, Marshall G, et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991;265:614-7.
27. Sinha RN, Patrick AW, Richardson L, Wallymahmed M, MacFarlane IA. A six-year follow-up study of smoking habits and microvascular complications in young adults with type 1 diabetes. Postgrad Med J 1997;73:293-4.
28. Microalbuminuria Collaborative Study Group. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: A cohort study. BMJ 1993;306:1235-9.
29. Scott LJ, Warram JH, Hanna LS, Laffel LM, Ryan L, Krolewski AS. A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 2001;50:2842-9.
30. Jones JM, Lawson ML, Daneman D, Olmsted MP, Rodin G. Eating disorders in adolescent females with and without type 1 diabetes: Cross sectional study. BMJ 2000;320:1563-6.
31. Rydall AC, Rodin GM, Olmsted MP, Devenyi RG, Daneman D. Disordered eating behavior and microvascular complications in young women with insulin-dependent diabetes mellitus. N Engl J Med 1997;336:1849-54.
32. Crow SJ, Keel PK, Kendall D. Eating disorders and insulin-dependent diabetes mellitus. Psychosomatics 1998;39:233-43.
33. Shield JP, Hunt LP, Baum JD, Pennock CA. Screening for diabetic microalbuminuria in routine clinical care: Which method? Arch Dis Child 1995;72:524-5.
34. Gatling W, Knight C, Hill RD. Screening for early diabetic nephropathy: Which sample to detect microalbuminuria? Diabet Med 1985;2:451-5.
35. Houlihan CA, Tsalamandris C, Akdeniz A, Jerums G. Albumin to creatinine ratio: A screening test with limitations. Am J Kidney Dis 2002;39:1183-9.
36. Lawson ML, Sochett EB, Chait PG, Balfe JW, Daneman D. Effect of puberty on markers of glomerular hypertrophy and hypertension in IDDM. Diabetes 1996;45:51-5.
37. Danne T, Kordonouri O. Controversies on the pathogenesis of diabetic angiopathy: Which treatment for normotensive adolescents with microalbuminuria and type 1 diabetes? J Pediatr Endocrinol Metab 1998;11(Suppl 2):347-63.
38. Rudberg S, Dahlquist G. Determinants of progression of microalbuminuria in adolescents with IDDM. Diabetes Care 1996;19:369-71.
39. Cook J, Daneman D, Spino M, Sochett E, Perlman K, Balfe JW. Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. J Pediatr 1990;117:39-45.
40. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995;99:497-504.
41. The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996;39:587-93.
42. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999;319:24-5.
43. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993;341:1306-9.
44. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703-20.
45. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989;107:237-43.
46. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-6.
47. Buxton MJ, Sculpher MJ, Ferguson BA, et al. Screening for treatable diabetic retinopathy: A comparison of different methods. Diabet Med 1991;8:371-7.
48. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
49. Duck SC, Wei FF, Parke J, Swick HM. Role of height and glycosylated hemoglobin in abnormal nerve conduction in pediatric patients with type I diabetes mellitus after 4-9 yr of disease. Diabetes Care 1991;14:386-92.
50. Donaghue KC, Fung AT, Fairchild JM, Howard NJ, Silink M. Prospective assessment of autonomic and peripheral nerve function in adolescents with diabetes. Diabet Med 1996;13:65-71.
51. Karachaliou F, Karavanaki K, Greenwood R, Baum JD. Consistency of pupillary abnormality in children and adolescents with diabetes. Diabet Med 1997;14:849-53.
52. Olsen BS, Sjolie A, Hougaard P, et al. A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. J Diabetes Complications 2000;14:295-300.
53. Solders G, Thalme B, Aguirre-Aquino M, Brandt L, Berg U, Persson A. Nerve conduction and autonomic nerve function in diabetic children. A 10-year follow-up study. Acta Paediatr 1997;86:361-6.
54. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001;24:250-6.
55. Abraha A, Schultz C, Konopelska-Bahu T, et al. Glycaemic control and familial factors determine hyperlipidaemia in early childhood diabetes. Oxford Regional Prospective Study of Childhood Diabetes. Diabet Med 1999;16:598-604.
56. Lipman TH, Hayman LL, Fabian CV, et al. Risk factors for cardiovascular disease in children with Type I diabetes. Nurs Res 2000;49:160-6.
57. Frank M. Factors associated with non-compliance with a medical follow-up regimen after discharge from a pediatric diabetse clinic. Can J Diabetes Care 1996;20:13-20.
58. Pacaud D, McConnell B, Huot C, et al. Transition from pediatric to adult care for insulin-dependent diabetes patients. Can J Diabetes Care 1996;20:14-20.
59. Kordonouri O, Klinghammer A, Lang EB, Gruters-Kieslich A, Grabert M, Holl RW. Thyroid Autoimmunity in Children and Adolescents With Type 1 Diabetes: A multicenter survey. Diabetes Care 2002;25:1346-50.
60. Marks SD, Girgis R, Couch RM. Screening for Adrenal Antibodies in Children With Type 1 Diabetes and Autoimmune Thyroid Disease. Diabetes Care 2003;26:3187-8.
61. Barera G, Bonfanti R, Viscardi M, et al. Occurrence of celiac disease after onset of type 1 diabetes: A 6-year prospective longitudinal study. Pediatrics 2002;109:833-8.
62. Hansen D, Bennedbaek FN, Hansen LK, et al. High prevalence of coeliac disease in Danish children with type I diabetes mellitus. Acta Paediatr 2001;90:1238-43.
63. Gillett PM, Gillett HR, Israel DM, et al. High prevalence of celiac disease in patients with type 1 diabetes detected by antibodies to endomysium and tissue transglutaminase. Can J Gastroenterol 2001;15:297-301.
64. Aktay AN, Lee PC, Kumar V, Parton E, Wyatt DT, Werlin SL. The prevalence and clinical characteristics of celiac disease in juvenile diabetes in Wisconsin. J Pediatr Gastroenterol Nutr 2001;33:462-5.
65. Spiekerkoetter U, Seissler J, Wendel U. General screening for celiac disease is advisable in children with type 1 diabetes. Horm Metab Res 2002;34:192-5.
66. Jaeger C, Hatziagelaki E, Petzoldt R, Bretzel RG. Comparative analysis of organ-specific autoantibodies and celiac disease - associated antibodies in type 1 diabetic patients, their first-degree relatives, and healthy control subjects. Diabetes Care 2001;24:27-32.
67. Carlsson AK, Axelsson IE, Borulf SK, et al. Prevalence of IgA-antiendomysium and IgA-antigliadin autoantibodies at diagnosis of insulin-dependent diabetes mellitus in Swedish children and adolescents. Pediatrics 1999;103:1248-52.
68. Hill I, Fasano A, Schwartz R, Counts D, Glock M, Horvath K. The prevalence of celiac disease in at-risk groups of children in the United States. J Pediatr 2000;136:86-90.
69. Fabiani E, Taccari LM, Ratsch IM, Di Giuseppe S, Coppa GV, Catassi C. Compliance with gluten-free diet in adolescents with screening-detected celiac disease: A 5-year follow-up study. J Pediatr 2000;136:841-3.
70. Saukkonen T, Vaisanen S, Akerblom HK, Savilahti E; Childhood Diabetes in Finland Study Group. Coeliac disease in children and adolescents with type 1 diabetes: A study of growth, glycaemic control, and experiences of families. Acta Paediatr 2002;91:297-302.
71. Amin R, Murphy N, Edge J, Ahmed ML, Acerini CL, Dunger DB. A longitudinal study of the effects of a gluten-free diet on glycemic control and weight gain in subjects with type 1 diabetes and celiac disease. Diabetes Care 2002;25:1117-22.
72. Mohn A, Cerruto M, Lafusco D, et al. Celiac disease in children and adolescents with type I diabetes: Importance of hypoglycemia. J Pediatr Gastroenterol Nutr 2001;32:37-40.
73. Savage PJ, Bennett PH, Senter RG, Miller M. High prevalence of diabetes in young Pima Indians: Evidence of phenotypic variation in a genetically isolated population. Diabetes 1979;28:937-42.
74. Dean HJ, Mundy RL, Moffatt M. Non-insulin-dependent diabetes mellitus in Indian children in Manitoba. CMAJ 1992;147:52-7.
75. Dean HJ, Young TK, Flett B, Wood-Steiman P. Screening for type-2 diabetes in aboriginal children in northern Canada. Lancet 1998;352:1523-4.
76. Harris SB, Perkins BA, Whalen-Brough E. Non-insulin-dependent diabetes mellitus among First Nations children. New entity among First Nations people of north western Ontario. Can Fam Physician 1996;42:869-76.
77. Smith WG, Gowanlock W, Babcock K. Type 2 diabetes in First Nations children: A collaborative effort to assess and prevent disease. Paediatr Child Health 2001;6:755-9.
78. Dannenbaum D, Verronneau M, Torrie J, et al. Comprehensive computerized diabetes registry. Serving the Cree of Eeyou Istchee (eastern James Bay). Can Fam Physician 1999;45:364-70.
79. Delisle HF, Ekoe JM. Prevalence of non-insulin-dependent diabetes mellitus and impaired glucose tolerance in two Algonquin communities in Quebec. CMAJ 1993;148:41-7.
80. Fagot-Campagna A. Emergence of type 2 diabetes mellitus in children: Epidemiological evidence. J Pediatr Endocrinol Metab 2000;13(Suppl 6):1395-402.
81. Krakoff J, Lindsay RS, Looker HC, Nelson RG, Hanson RL, Knowler WC. Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes. Diabetes Care 2003;26:76-81.
82. Owada M, Hanaoka Y, Tanimoto Y, Kitagawa T. Descriptive epidemiology of non-insulin dependent diabetes mellitus detected by urine glucose screening in school children in Japan. Acta Paediatr Jpn 1990;32:716-24.
83. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: An epidemiologic review and a public health perspective. J Pediatr 2000;136:664-72.
84. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002;346:802-10.
85. McCance DR, Pettitt DJ, Hanson RL, Jacobsson LT, Bennett PH, Knowler WC. Glucose, insulin concentrations and obesity in childhood and adolescence as predictors of NIDDM. Diabetologia 1994;37:617-23.
86. Pettitt DJ, Moll PP, Knowler WC, et al. Insulinemia in children at low and high risk of NIDDM. Diabetes Care 1993;16:608-15.
87. Hanley AJ, Harris SB, Gittelsohn J, Wolever TM, Saksvig B, Zinman B. Overweight among children and adolescents in a Native Canadian community: Prevalence and associated factors. Am J Clin Nutr 2000;71:693-700.
88. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 2001;138:38-44.
89. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:1017-23.
90. Dabelea D, Hanson RL, Lindsay RS, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: A study of discordant sibships. Diabetes 2000;49:2208-11.
91. Young TK, Martens PJ, Taback SP, et al. Type 2 diabetes mellitus in children: Prenatal and early infancy risk factors among native Canadians. Arch Pediatr Adolesc Med 2002;156:651-5.
92. Stoddart ML, Blevins KS, Lee ET, Wang W, Blackett PR. Association of acanthosis nigricans with hyperinsulinemia compared with other selected risk factors for type 2 diabetes in Cherokee Indians: The Cherokee Diabetes Study. Diabetes Care 2002;25:1009-14.
93. Sellers E, Eisenbarth G, Young TK, Dean HJ. Diabetes-associated autoantibodies in aboriginal children. Lancet 2000;355:1156.
94. Hathout EH, Thomas W, El Shahawy M, Nahab F, Mace JW. Diabetic autoimmune markers in children and adolescents with type 2 diabetes. Pediatrics 2001;107:e102.
95. Pinhas-Hamiel O, Dolan LM, Zeitler PS. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. Diabetes Care 1997;20:484-6.
96. Sellers EA, Dean HJ. Diabetic ketoacidosis: A complication of type 2 diabetes in Canadian aboriginal youth. Diabetes Care 2000;23:1202-4.
97. Sellers EA, Triggs-Raine B, Rockman-Greenberg C, Dean HJ. The prevalence of the HNF-1alpha G319S mutation in Canadian aboriginal youth with type 2 diabetes. Diabetes Care 2002;25:2202-6.
98. Owen KR, Stride A, Ellard S, Hattersley AT. Etiological investigation of diabetes in young adults presenting with apparent type 2 diabetes. Diabetes Care 2003;26:2088-93.
99. Campbell k, Waters E, O'Meara S, et al. Interventions for preventing obesity in children. Cochrane Database Syst Rev 2002;26:2088-93.
100. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:E55.
101. Kay JP, Alemzadeh R, Langley G, D'angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001;50:1457-61.
102. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: Amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002;87:1555-9.
103. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001;29:160-9.
104. Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001;86:3595-8.
105. Macaulay AC, Harris SB, Levesque L, et al. Primary prevention of type 2 diabetes: A tale of 2 Aboriginal communities in Canada. Can J Diabetes 2003;27:464-75.
106. Anderson KA, Dean HJ. The effect of diet and exercise on a native youth with poorly controlled non-insulin dependent diabetes mellitus. Beta Release 1990;14:105-6.
107. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: A randomized controlled trial. Diabetes Care 2002;25:89-94.
108. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000;30:48-53.
109. Yokoyama H, Okudaira M, Otani T, et al. Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care 1997;20:844-7.
110. Bulloch B, Postl BD, Ogborn MR. Excess prevalence of non diabetic renal disease in native American children in Manitoba. Pediatr Nephrol 1996;10:702-4.
111. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989;107:244-9.
112. Smith SA, Poland GA. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care 2000;23:95-108.
113. National Advisory Committee on Immunization. Canadian Immunization Guide, 6th edn. Ottawa: Canadian Medical Association, 2002. 〈www.phac-aspc.gc.ca/ publicat/cig-gci/index.html〉 (Version current at November 22, 2004).
114. Overturf GD. American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: Prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics 2000;106:367-76.
115. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49:1-35.
116. Levy-Marchal C, Patterson CC, Green A. Geographical variation of presentation at diagnosis of type 1 diabetes in children: The EURODIAB study. European and Dibetes. Diabetologia 2001;44(Suppl 3):B75-B80.
117. Smith CP, Firth D, Bennett S, Howard C, Chisholm P. Ketoacidosis occurring in newly diagnosed and established diabetic children. Acta Paediatr 1998;87:537-41.
118. Pinkey JH, Bingley PJ, Sawtell PA, Dunger DB, Gale EA. Presentation and progress of childhood diabetes mellitus: A prospective population-based study. The Bart's-Oxford Study Group. Diabetologia 1994;37:70-4.
119. Golden MP, Herrold AJ, Orr DP. An approach to prevention of recurrent diabetic ketoacidosis in the pediatric population. J Pediatr 1985;107:195-200.
120. Flood RG, Chiang VW. Rate and prediction of infection in children with diabetic ketoacidosis. Am J Emerg Med 2001;19:270-3.
121. Hoffman WH, O'Neill P, Khoury C, Bernstein SS. Service and education for the insulin-dependent child. Diabetes Care 1978;1:285-8.
122. Keenan HT, Foster CM, Bratton SL. Social factors associated with prolonged hospitalization among diabetic children. Pediatrics 2002;109:40-4.
123. Dunger DB, Sperling MA, Acerini CL, et al. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child 2004;89:188-94.
124. Rosenbloom AL. Intracerebral crises during treatment of diabetic ketoacidosis. Diabetes Care 1990;13:22-33.
125. Edge JA, Hawkins MM, Winter DL, Dunger DB. The risk and outcome of cerebral oedema developing during diabetic ketoacidosis. Arch Dis Child 2001;85:16-22.
126. Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med 2001;344:264-9.
127. Harris GD, Fiordalisi I. Physiologic management of diabetic ketoacidemia. A 5-year prospective pediatric experience in 231 episodes. Arch Pediatr Adolesc Med 1994;148:1046-52.
128. Hale PM, Rezvani I, Braunstein AW, Lipman TH, Martinez N, Garibaldi L. Factors predicting cerebral edema in young children with diabetic ketoacidosis and new onset type I diabetes. Acta Paediatr 1997;86:626-31.